Announcements Trials
Browse Landscape

Phase

Phase 2 296Phase 3 77Phase 1/2 73Phase 1 45Phase NA 43Phase 2/3 5Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1

Interventions

Saline Solution 10Docetaxel 10Bevacizumab 9nilotinib 8enzalutamide 8Paclitaxel 8Letrozole 8Fentanyl 8Everolimus 8Cyclophosphamide 8Carboplatin 8Bupivacaine 8Lidocaine 7Sodium Chloride 6Oxycodone 6Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 6Erlotinib Hydrochloride 6Dexamethasone 6Capecitabine 6Trastuzumab 5Tobacco Use Cessation Devices 5Surveys and Questionnaires 5Nivolumab 5Hydromorphone 5Adalimumab 5fludarabine 4Zoledronic Acid 4Tranexamic Acid 4Tacrolimus 4Rocuronium 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Has results × Radiotherapy × Clear all
NCT00686725 2017-06-14

Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)

Merck Sharp & Dohme LLC

Phase 4 Completed
99 enrolled 15 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡